Cargando…
Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing
BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic diso...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565546/ https://www.ncbi.nlm.nih.gov/pubmed/30968598 http://dx.doi.org/10.1002/mgg3.684 |
_version_ | 1783426666864836608 |
---|---|
author | Hong, Sha Wang, Li Zhao, Dongying Zhang, Yonghong Chen, Yan Tan, Jintong Liang, Lili Zhu, Tianwen |
author_facet | Hong, Sha Wang, Li Zhao, Dongying Zhang, Yonghong Chen, Yan Tan, Jintong Liang, Lili Zhu, Tianwen |
author_sort | Hong, Sha |
collection | PubMed |
description | BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic disorders in a pediatric setting. METHODS: Next‐generation sequencing tests are performed for 98 unrelated Chinese patients within their first year of life, who were admitted to Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, during a 2‐year period. RESULTS: Clinical indications for NGS tests included a range of medical concerns. The mean age was 4.4 ± 4.2 months of age for infants undergoing targeting specific (known) disease‐causing genes (TRS) analysis, and 4.4 ± 4.3 months of age for whole‐exome sequencing (WES) (p > 0.05). A molecular diagnosis is done in 72 infants (73.47%), which finds a relatively high yield with phenotypes of metabolism/homeostasis abnormality (HP: 0001939) (odds ratio, 1.83; 95% CI, 0.56–6.04; p = 0.32) and a significantly low yield with atypical symptoms (without a definite HPO term) (odds ratio, 0.08; 95% CI, 0.01–0.73; p = 0.03). TRS analysis provides molecular yields higher than WES (p = 0.01). Ninety‐eight different mutations are discovered in 72 patients. Twenty‐seven of them have not been reported previously. Nearly half (43.06%, 31/72) of the patients are found to carry 11 common disorders, mostly being inborn errors of metabolism (IEM) and neurogenetic disorders and all of them are observed through TRS analysis. Eight positive cases are identified through WES, and all of them are sporadic, of highly variable phenotypes and severity. There are 26 patients with negative findings in this study. CONCLUSION: This study provides evidence that NGS can yield high success rates in a tertiary pediatric setting, but suggests that the scope of known Mendelian conditions may be considerably broader than currently recognized. |
format | Online Article Text |
id | pubmed-6565546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65655462019-06-20 Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing Hong, Sha Wang, Li Zhao, Dongying Zhang, Yonghong Chen, Yan Tan, Jintong Liang, Lili Zhu, Tianwen Mol Genet Genomic Med Original Articles BACKGROUND: Rare diseases are complex disorders with huge variability in clinical manifestations. Decreasing cost of next‐generation sequencing (NGS) tests in recent years made it affordable. We witnessed the diagnostic yield and clinical use of different NGS strategies on a myriad of monogenic disorders in a pediatric setting. METHODS: Next‐generation sequencing tests are performed for 98 unrelated Chinese patients within their first year of life, who were admitted to Xin Hua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, during a 2‐year period. RESULTS: Clinical indications for NGS tests included a range of medical concerns. The mean age was 4.4 ± 4.2 months of age for infants undergoing targeting specific (known) disease‐causing genes (TRS) analysis, and 4.4 ± 4.3 months of age for whole‐exome sequencing (WES) (p > 0.05). A molecular diagnosis is done in 72 infants (73.47%), which finds a relatively high yield with phenotypes of metabolism/homeostasis abnormality (HP: 0001939) (odds ratio, 1.83; 95% CI, 0.56–6.04; p = 0.32) and a significantly low yield with atypical symptoms (without a definite HPO term) (odds ratio, 0.08; 95% CI, 0.01–0.73; p = 0.03). TRS analysis provides molecular yields higher than WES (p = 0.01). Ninety‐eight different mutations are discovered in 72 patients. Twenty‐seven of them have not been reported previously. Nearly half (43.06%, 31/72) of the patients are found to carry 11 common disorders, mostly being inborn errors of metabolism (IEM) and neurogenetic disorders and all of them are observed through TRS analysis. Eight positive cases are identified through WES, and all of them are sporadic, of highly variable phenotypes and severity. There are 26 patients with negative findings in this study. CONCLUSION: This study provides evidence that NGS can yield high success rates in a tertiary pediatric setting, but suggests that the scope of known Mendelian conditions may be considerably broader than currently recognized. John Wiley and Sons Inc. 2019-04-09 /pmc/articles/PMC6565546/ /pubmed/30968598 http://dx.doi.org/10.1002/mgg3.684 Text en © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Hong, Sha Wang, Li Zhao, Dongying Zhang, Yonghong Chen, Yan Tan, Jintong Liang, Lili Zhu, Tianwen Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title | Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title_full | Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title_fullStr | Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title_full_unstemmed | Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title_short | Clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
title_sort | clinical utility in infants with suspected monogenic conditions through next‐generation sequencing |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565546/ https://www.ncbi.nlm.nih.gov/pubmed/30968598 http://dx.doi.org/10.1002/mgg3.684 |
work_keys_str_mv | AT hongsha clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT wangli clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT zhaodongying clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT zhangyonghong clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT chenyan clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT tanjintong clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT lianglili clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing AT zhutianwen clinicalutilityininfantswithsuspectedmonogenicconditionsthroughnextgenerationsequencing |